FDA Plans to Encourage Use of Compounders Registered as "Outsourcing Facilities"

Published Online: Monday, January 13, 2014
Under the Drug Quality and Security Act, signed into law by President Obama on November 27, 2013, large-scale compounding pharmacies can register with the FDA as “outsourcing facilities.” Although this registration is voluntary, the FDA plans to encourage physicians and other health care providers to use only large-scale compounders that have registered with it.

Compounding pharmacies that register with the agency will be subject to federal quality standards known as current good manufacturing practice and will be subject to FDA inspection on a risk-based schedule, noted FDA Commissioner Margaret Hamburg, MD, in a blog post on December 2, 2013.

“If compounders register with FDA as outsourcers, hospitals and other health care providers will be able to provide their patients with drugs that were compounded in facilities that are subject to FDA oversight and federal requirements for current good manufacturing practice, among others,” Dr. Hamburg wrote. “To that end, we will be encouraging health care providers and health networks to consider purchasing compounded products from facilities that are registered with FDA and subject to risk-based inspections.”

When asked during a conference call with reporters how the agency will encourage use of the registered facilities, Dr. Hamburg was vague, but hinted that it might seek to encourage insurers to favor drugs produced by the registered facilities when it comes to reimbursement.

Latest Articles
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.
Chronic kidney disease incidence has grown faster than many of its common comorbidities such as diabetes and hypertension, and medications may be an underappreciated driver of this growth.
President Barack Obama’s fiscal year 2017 budget proposal calls for an additional $1.1 billion to combat the nation’s spiraling opioid epidemic.
Baxter International is voluntarily recalling intravenous solution due to leaking containers and the potential for particulate matter.
Latest Issues